Exploring The Potential of LILRB1 as A Drug Target Or Biomarker

Target Name: LILRB1

NCBI ID: G10859

LILRB1

Exploring The Potential of LILRB1 as A Drug Target Or Biomarker

LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1) is a protein that is expressed in various tissues throughout the body, including the nervous system, endothelial cells, and various immune cells. It is a member of the Leukocyte immunoglobulin-like receptor subfamily B and is responsible for cell signaling and immune responses.

Recent studies have suggested that LILRB1 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its involvement in various signaling pathways that are involved in these conditions.

One of the main functions of LILRB1 is its role in the immune system. It is a member of the immunoglobulin superfamily and is involved in the development and regulation of antibodies, which are critical for the immune response. LILRB1 has been shown to play a role in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In addition to its role in immune system function, LILRB1 is also involved in cell signaling and cell-to-cell interactions. It is a member of the Ligand-gene axis, which is a critical signaling pathway that links the cell surface to intracellular signaling pathways. This pathway is involved in various cellular processes, including cell division, migration, and apoptosis.

The role of LILRB1 in cell signaling and interactions is also of interest in the context of neurodegenerative diseases. As these conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, LILRB1 may be involved in the regulation of neurodegeneration.

Recent studies have also suggested that LILRB1 may be involved in cancer development. It has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. This is due to its role in cell signaling and its expression in various types of cancer cells.

Despite its involvement in these conditions, LILRB1 has not yet been fully characterized as a drug target or biomarker. Further research is needed to fully understand its role in these processes and to explore its potential as a drug or biomarker.

In conclusion, LILRB1 is a protein that is involved in various signaling pathways and cellular processes throughout the body. Its involvement in the immune system, cell signaling, and cell-to-cell interactions makes it of interest as a potential drug target or biomarker for various diseases. Further research is needed to fully understand its role in these processes and to explore its potential as a therapeutic agent.

Protein Name: Leukocyte Immunoglobulin Like Receptor B1

Functions: Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251)

The "LILRB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets